Paper Details

  1. Home
  2. Paper Details

Cost Effectiveness of Transplant, Conventional Chemotherapy, and Novel Agents in Multiple Myeloma: A Systematic Review.

Author: FuShuangshuang, LairsonDavid R, WangMichael, WuChi-Fang

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

For transplant-eligible multiple myeloma (MM) patients, a transplant is a cost-effective first-line treatment option. While there is a lack of cost-effectiveness analyses comparing novel agents in first-line treatment, bortezomib-based regimens, lenalidomide plus dexamethasone, and pomalidomide plus dexamethasone are each cost-effective compared with dexamethasone alone in the second-line setting.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Treatments for multiple myeloma (MM) have been rapidly evolving. Newly developed treatment regimens are likely to be more effective but also cost more than conventional therapies. OBJECTIVE: We conducted a systematic review to compare the cost effectiveness of different classes of MM tr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s40273-019-00828-y

データ提供：米国国立医学図書館（NLM）

Cost-Effective Solutions in Multiple Myeloma: Navigating the Treatment Desert

Multiple myeloma, a cancer of plasma cells, presents a challenging landscape for treatment, much like a vast and unforgiving desert. This systematic review, a guide through the complex world of treatment options, examines the cost-effectiveness of various therapies for multiple myeloma, from conventional chemotherapy to newer agents and stem cell transplantation. The researchers, in their quest to find the most effective and affordable treatments, analyzed a wealth of data, seeking to guide clinicians in their decision-making process.

Stem Cell Transplantation: A Cost-Effective Oasis

The review's findings, like a well-mapped oasis in the desert, suggest that stem cell transplantation is a cost-effective option for transplant-eligible patients, providing a significant benefit in terms of quality-adjusted life years (QALYs). This is akin to discovering a source of life-sustaining water in a harsh environment. The authors, in their analysis of cost-effectiveness, highlight the importance of considering both the cost and the benefits of various treatment options.

New Agents: Promise and Challenges

While newer agents show promise in treating multiple myeloma, their cost-effectiveness remains uncertain. This is like encountering a promising but uncharted route in the desert, requiring further exploration to assess its feasibility and value. The researchers emphasize the need for further cost-effectiveness analyses to determine the optimal treatment strategy for patients with multiple myeloma.

Dr. Camel's Conclusion

This systematic review, like a caravan navigating a complex desert terrain, offers valuable insights into the cost-effectiveness of various treatment options for multiple myeloma. Stem cell transplantation emerges as a cost-effective solution for eligible patients, while newer agents hold promise but require further investigation. The authors' comprehensive analysis serves as a valuable guide for clinicians, emphasizing the importance of balancing cost and efficacy in the treatment of this challenging disease.

Date :
  1. Date Completed 2020-08-19
  2. Date Revised 2020-08-19
Further Info :

Pubmed ID

31392666

DOI: Digital Object Identifier

10.1007/s40273-019-00828-y

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.